Real-World Outcomes of [177Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer.

Clément Bailly¹, Lavinia Vija², François Somme³, Vincent Massard⁴, Philippe Barthélémy⁵, Anne-Laure Giraudet⁶, Yann Godbert⁷, Aude Fléchon⁸, Sylvie Girault⁹, Sophie Abadie-Lacourtoisie¹⁰, Caroline Viala¹¹, Alix Douillet¹², Stephanie Chêne¹², Pierre Olivier¹³, Guilhem Roubaud¹⁴

¹Nuclear Medicine Department, Nantes University Hospital, Nantes, France; clement.bailly@chu-nantes.fr.

²Department of Nuclear Medecine, Oncopole Claudius Regaud, Toulouse, France.

³Nuclear Medicine and Molecular Imaging, Institut Strauss, Strasbourg, France.

⁴Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.

⁵Department of Medical Oncology, University Hospital Strasbourg, Strasbourg, France.

⁶Lumen Nuclear Medicine Department, Centre Léon Bérard, Lyon, France.

⁷Department of Thyroid Oncology and Nuclear Medicine, Institut Bergonié, Bordeaux, France.

⁸Department of Medical Oncology, Urological Oncology Centre Léon Bérard, Lyon, France.

⁹Department of Nuclear Medicine, ICO Pays de la Loire, Angers, France.

¹⁰ICO Paul Papin, Angers, France.

¹¹Nantes University Hospital, Nantes, France.

¹²Medical Department, Novartis, Rueil-Malmaison, France.

¹³Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, France; and.

¹⁴Department of Medical Oncology, Institut Bergonié, Bordeaux, France.

PubMed DOI

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) remains challenging to treat, especially after failure of standard therapies, such as androgen receptor pathway inhibitors and taxane-based chemotherapy. Radiopharmaceutical therapy with [177Lu]Lu-PSMA-617 targets prostate-specific membrane antigen (PSMA)-positive tumor cells. In the VISION trial, [177Lu]Lu-PSMA-617 has demonstrated significa…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.